港股持续高温，港股ETF冰火两重天，这些产品“越跌越买”

Group 1 - The Hong Kong stock market has seen significant activity in 2023, particularly in Q2, with many A-share companies listing in Hong Kong, leading to increased investment through ETF products [1][2] - Since April, over 100 ETF products focused on the Hong Kong market have been launched, with nearly 60% of these products experiencing growth in their share sizes, totaling an increase of 184.04 million shares, reaching a total size of 428 billion shares [2][3] - The influx of capital from mainland investors has supported the recovery of the Hong Kong market after significant fluctuations, including a drop of over 13% in the Hang Seng Index in early April [2][3] Group 2 - Specific sectors such as technology and internet-related ETFs have shown notable growth, while healthcare and pharmaceutical-related products have seen a decline in share sizes [3][9] - The Hong Kong Internet ETF (159792) has seen a share increase of 64.78 million shares since April, making it the largest product in terms of share size among Hong Kong-focused ETFs [4][5] - Conversely, the Hang Seng Medical ETF has experienced a significant decrease of 97.75 million shares, despite a year-to-date increase of 32% in its price [10][11] Group 3 - The innovative pharmaceutical sector has attracted attention, with the Hong Kong Innovative Pharmaceutical ETF (159217) growing by 24.31 million shares, reflecting a 192% increase [7][9] - Despite the overall growth in certain ETFs, many have faced price declines, with several products tracking the Hang Seng Technology Index dropping over 5% since April [5][10] - The trend of "buying the dip" is evident in technology and internet-related ETFs, while funds have been withdrawing from healthcare and pharmaceutical sectors [3][9]